JP2019527231A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527231A5 JP2019527231A5 JP2019504928A JP2019504928A JP2019527231A5 JP 2019527231 A5 JP2019527231 A5 JP 2019527231A5 JP 2019504928 A JP2019504928 A JP 2019504928A JP 2019504928 A JP2019504928 A JP 2019504928A JP 2019527231 A5 JP2019527231 A5 JP 2019527231A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- subject
- sarcoma
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369639P | 2016-08-01 | 2016-08-01 | |
| US62/369,639 | 2016-08-01 | ||
| PCT/US2017/044513 WO2018026663A1 (en) | 2016-08-01 | 2017-07-28 | Combinations for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019527231A JP2019527231A (ja) | 2019-09-26 |
| JP2019527231A5 true JP2019527231A5 (enExample) | 2020-09-10 |
Family
ID=61073280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019504928A Pending JP2019527231A (ja) | 2016-08-01 | 2017-07-28 | がんを治療するための組み合わせ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190185567A1 (enExample) |
| EP (1) | EP3490561A4 (enExample) |
| JP (1) | JP2019527231A (enExample) |
| CN (1) | CN109689056A (enExample) |
| WO (1) | WO2018026663A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3529245A4 (en) | 2016-10-24 | 2020-12-23 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THE LATEST |
| MA47212A (fr) | 2017-01-06 | 2019-11-13 | Yumanity Therapeutics Inc | Méthodes de traitement de troubles neurologiques |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| US11247990B1 (en) | 2017-12-07 | 2022-02-15 | Array Biopharma Inc | Bicyclic fused pyridine compounds as inhibitors of TAM kinases |
| ES3043183T3 (en) | 2018-03-23 | 2025-11-25 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| UY38349A (es) | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
| MA54829A (fr) | 2019-01-24 | 2021-12-01 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| US20230078764A1 (en) * | 2019-03-22 | 2023-03-16 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| US11419844B2 (en) | 2019-11-19 | 2022-08-23 | Provectus Pharmatech, Inc. | Halogenated xanthene composition and method for treating hematologic cancers |
| AU2019474803B2 (en) * | 2019-11-19 | 2024-11-07 | Provectus Pharmatech, Inc. | Composition and method for treating hematologic cancers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ517202A (en) * | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| AU2015203324B2 (en) * | 2009-07-20 | 2016-07-28 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| PT2769737T (pt) * | 2009-07-20 | 2017-06-29 | Bristol Myers Squibb Co | Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas |
| US20130156768A1 (en) * | 2010-08-26 | 2013-06-20 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases |
| AU2012262520A1 (en) * | 2011-05-27 | 2014-01-23 | Cytocure Llc | Methods, compositions, and kits for the treatment of cancer |
| EA023521B1 (ru) * | 2011-11-14 | 2016-06-30 | Сефалон, Инк. | ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ |
| EP3027623A4 (en) * | 2013-08-02 | 2017-03-01 | Ignyta, Inc. | METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS |
| US20170175197A1 (en) * | 2014-01-29 | 2017-06-22 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| US10231965B2 (en) * | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
-
2017
- 2017-07-28 EP EP17837447.6A patent/EP3490561A4/en not_active Withdrawn
- 2017-07-28 WO PCT/US2017/044513 patent/WO2018026663A1/en not_active Ceased
- 2017-07-28 JP JP2019504928A patent/JP2019527231A/ja active Pending
- 2017-07-28 CN CN201780056390.6A patent/CN109689056A/zh active Pending
- 2017-07-28 US US16/322,926 patent/US20190185567A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019524851A5 (enExample) | ||
| CN105849110B (zh) | 使用溴结构域和额外终端(bet)蛋白抑制剂的用于癌症的组合疗法 | |
| ES2751300T3 (es) | Formulación sublingual de riluzol | |
| RU2012151571A (ru) | Лекарственные препараты для лечения рака | |
| JP2022533578A5 (enExample) | ||
| CN103547315A (zh) | 用于治疗腺样囊性癌的4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮 | |
| TWI762784B (zh) | Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途 | |
| RU2005128791A (ru) | Лекарственные формы, содержащие ag013736 | |
| CN102421427A (zh) | 用于治疗特定癌症的包含rdea119/bay869766的药物组合 | |
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| US20090005406A1 (en) | Cancer Treatment Method | |
| JP2004510761A5 (enExample) | ||
| KR102744499B1 (ko) | 비인두암을 치료하기 위한 퀴놀린 유도체 | |
| TW202042810A (zh) | 一種含cdk4/6抑制劑的組合物與阿那曲唑聯合在製備治療腫瘤疾病的藥物中的用途 | |
| ES2981004T3 (es) | Composición que comprende un extracto de proteoglicanos de algas verdeazuladas y uso de la misma | |
| WO2022123427A1 (en) | Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof | |
| PT1757283E (pt) | Potenciador do efeito antitumoral, agente antitumoral e método para a terapia do cancro | |
| Chao-Cheng et al. | Lipoblastomatosis combined with intestinal neuronal dysplasia | |
| CN118019537A (zh) | Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途 | |
| RU2718048C2 (ru) | Противоопухолевое терапевтическое средство | |
| TW202547488A (zh) | 於癌症的治療中之化合物Ｉａ和拓樸異構酶Ｉ抑制劑的組合 | |
| JP2025533334A5 (enExample) | ||
| ES2894841T3 (es) | Compuestos y composiciones para su uso en el tratamiento de enfermedades mediadas por BCAT1 | |
| Cozzi et al. | Systemic Sclerosis | |
| CN119421707A (zh) | (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗癌症中的用途 |